Jeanine M L Roodhart
Overview
Explore the profile of Jeanine M L Roodhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Nassau S, Zwart K, van der Baan F, Vink G, Elferink M, Snaebjornsson P, et al.
Int J Cancer
. 2025 Mar;
PMID: 40081858
The treatment landscape for metastatic colorectal cancer (mCRC) has evolved into a continuum of care with an essential role for biomarkers and molecular subgroups. Treatment guidelines are primarily based on...
2.
Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39929672
Background: Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). A significant proportion of patients show resistance,...
3.
Torang A, van de Weerd S, Lammers V, van Hooff S, van den Berg I, van den Bergh S, et al.
Mol Oncol
. 2024 Dec;
PMID: 39720854
Colorectal cancer (CRC) is a significant contributor to cancer-related mortality, emphasizing the need for advanced biomarkers to guide treatment. As part of an international consortium, we previously categorized CRCs into...
4.
Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis
Smabers L, Huismans M, van Nieuwenhuijzen N, Minnema M, Kranenburg O, Koopman M, et al.
Eur J Cancer
. 2024 Oct;
212:115059.
PMID: 39368225
Background: Despite recent metastatic colorectal cancer (mCRC) therapeutic innovations a comprehensive synthesis of patient outcome and risk-benefit assessment of phase 1/2 trials is missing. The aim of this meta-analysis is...
5.
Kramer A, Greuter M, Schraa S, Vink G, Phallen J, Velculescu V, et al.
Ther Adv Med Oncol
. 2024 Aug;
16:17588359241266164.
PMID: 39175989
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative...
6.
Roodhart J, Koopman M
Lancet Oncol
. 2024 Aug;
25(9):1104-1105.
PMID: 39116901
No abstract available.
7.
van de Weerd S, Torang A, van den Berg I, Lammers V, van den Bergh S, Brouwer N, et al.
Int J Cancer
. 2024 Aug;
156(2):456-466.
PMID: 39115332
The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per...
8.
Franken I, van der Baan F, Vink G, May A, van Grevenstein W, Koopman M, et al.
Eur J Cancer
. 2024 Jul;
208:114207.
PMID: 39024724
Aim: Adjuvant chemotherapy has been advised for high-risk stage II and III colon cancer since 2004. After the IDEA study showed no clinically relevant difference in outcome, reduction of adjuvant...
9.
Zwart K, van Nassau S, van der Baan F, Koopman M, Snaebjornsson P, van Gestel A, et al.
Br J Cancer
. 2024 May;
131(1):110-116.
PMID: 38769450
Background: Encorafenib-cetuximab has been approved for pretreated BRAF-mutated metastatic colorectal cancer (mCRC) patients based on efficacy demonstrated in the randomized phase III BEACON trial. The aim of this real-world effectiveness...
10.
Boon N, Oliveira R, Korner P, Kochavi A, Mertens S, Malka Y, et al.
Science
. 2024 May;
384(6697):785-792.
PMID: 38753784
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown....